Based on the results of the LEADER trial, where would you position liraglutide in the ADA/EASD sequencing algorithm for antidiabetic agents?

Based on the results of the LEADER trial, where would you position liraglutide in the ADA/EASD sequencing algorithm for antidiabetic agents?

Based on the results of the LEADER trial, where would you position liraglutide in the ADA/EASD sequencing algorithm for antidiabetic agents?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Steve Bain, MD

Steve Bain, MD

Professor of Medicine (Diabetes)
College of Medicine
Swansea University
Swansea, UK